FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:280-281 July 22, 1993 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: We are writing about two instances in which we believe that good labeling practices have not been followed for nonprescription medications.

In the first instance, Sandoz Corporation is marketing new preparations of Triaminic Syrup and Triaminic Expectorant that are half the strength of the old formulation.¹ Presumably, the new formulation makes the medication easier to give to young children. Unfortunately, the label does not indicate that the new preparation is half the strength of the old one; it states only that the product is "new and improved." Furthermore, the label and color of both the new and . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.